RaphaelJAhmedzaiSHHesterJ. Cancer pain: part 1: pathophysiology; oncological, pharmacological, and psychological treatments: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Med2010; 11: 742–764.
7.
RaphaelJHesterJAhmedzaiSH. Cancer pain: part 2: physical, interventional and complimentary therapies; management in the community; acute, treatment-related and complex cancer pain. Pain Med2010; 11: 872–896.
AhmedzaiSHWalshD. Palliative medicine and modern cancer care. Semin Oncol2000; 27(1): 1–6.
10.
FerreiraKASLKimuraMTeixeiraMJ. The WHO analgesic ladder for cancer pain control, twenty years of use: how much pain relief does one get from it?Supp Care Cancer2006; 14: 1086–1093.
11.
BurtonAWHamidB. Current challenges in cancer pain management: does the WHO ladder approach still have relevance?Expert Rev Anticancer Ther2007; 7(11): 1501–1502.
12.
WiffenPJWeeBMooreRA. Oral morphine for cancer pain. Cochrane Database Syst Rev2013; 4: CD003868.
13.
CaraceniAHanksGKaasaS.; European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol2012; 13(2): e58–e68.
14.
WeissSCEmanuelLLFaircloughDL. Understanding the experience of pain in terminally ill patients. Lancet2001; 357: 1311–1315.
15.
GlarePWalshDSheehanD. The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. Am J Hosp Palliat Care2006; 23: 229–235.
16.
StannardC. Opioids in the UK: what’s the problem?BMJ2013; 347: f5108.
17.
BolandEEiserCEzaydiY. Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. J Pain Symptom Manage2013; 46: 671–680.
18.
SlootSBolandJSnowdenJA. Side effects of analgesia may significantly reduce quality of life in symptomatic multiple myeloma: a cross-sectional prevalence study. Support Care Cancer. Epub ahead of print 28August2014. DOI: 10.1007/s00520-014-2358-1.